Physician profile
Vir K Nanda
NPI 1386841963
$19,292.53
in general payments reported to CMS, 2019-2025
54 companies · $4,744 in 2025
The $4,744 reported for 2025 was more than what 81% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $624 · 2020: $418 · 2021: $1,053 · 2022: $1,558 · 2023: $2,791 · 2024: $8,104 · 2025: $4,744.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,680 · Food and Beverage: $4,635 · Debt Forgiveness: $3,388 · Long Term Medical Supply Or Device Loan: $2,250 · Education: $471 · Travel and Lodging: $214.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,680.00 |
| Food and Beverage | $4,634.67 |
| Debt Forgiveness | $3,388.32 |
| Long Term Medical Supply Or Device Loan | $2,249.91 |
| Education | $471.42 |
| Travel and Lodging | $214.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $5,716.37 | 2019-2024 | Trodelvy |
| Novartis Pharmaceuticals Corporation | $3,846.71 | 2019-2025 | |
| B. Braun Medical INC. | $3,388.32 | 2025 | |
| Janssen Biotech, INC. | $974.75 | 2019-2024 | Imbruvica, Darzalex, Tecvayli |
| E.R. Squibb & Sons, L.L.C. | $560.18 | 2019-2024 | Pomalyst, Opdivo, Reblozyl |
| Astellas Pharma US INC | $508.63 | 2019-2025 | Xospata, Vyloy |
| Celgene Corporation | $322.52 | 2020-2025 | Pomalyst, Reblozyl |
| Takeda Pharmaceuticals U.S.A., INC. | $289.06 | 2019-2023 | Iclusig, Ninlaro |
| Glaxosmithkline, LLC. | $277.47 | 2020-2023 | Zejula |
| Amgen INC. | $263.93 | 2020-2023 | Vectibix, Xgeva, Nplate |
| Pfizer INC. | $240.92 | 2019-2024 | |
| Incyte Corporation | $216.35 | 2019-2024 | Jakafi |
| Beigene USA, INC. | $201.10 | 2022-2024 | Brukinsa |
| Sumitomo Pharma America, INC. | $153.91 | 2023-2025 | Orgovyx |
| Eisai INC. | $153.00 | 2022-2025 |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vir Nanda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.